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Summary
Objectives
The aim of this study was to evaluate the effect of alexithymia 
and defence mechanisms on the quality of life of patients af-
fected by breast cancer at different stages of the disease.
Methods
A convenience sample of 110 patients with breast cancer was 
involved in the study: 41 were receiving adjuvant chemother-
apy after surgery, 29 had disease-free survival in follow-up and 
40 were receiving chemotherapy for metastatic disease. Qual-
ity of life, alexithymia and defence mechanisms were assessed 
using the following instruments: EORTC QLQ-C30-BR23, To-
ronto Alexithymia Scale (TAS-20) and Defense Mechanism 
Inventory (DMI). 
Results
Compared to the other groups, patients receiving chemotherapy 
for metastatic disease reported poorer quality of life in several 
domains, more severe cancer-related and treatment-related 
symptoms and higher levels of alexithymia. When the effect of 
other potential predictors was taken into account, TAS-20 dif-
ficulty in identifying feelings was significantly related to all the 
EORTC functional subscale. 
Conclusion
This study underlined the relevance of difficulty in emotional 
processing and defence mechanisms in modulating psychologi-
cal adjustment in women affected by breast cancer, suggesting 
that these might be potential targets of psychological interven-
tion for this population.
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Introduction
A diagnosis of breast cancer substantially affects patients’ 
quality of life and may produce various psychological 
consequences, such as changes in self-esteem and per-
sonal values and severe disturbances in body image. 
Consistent evidence has demonstrated that women with 
breast cancer who underwent to surgical therapy show 
low self-esteem, greater worries for body image and con-
cerns about the opinions of others 1-3. 
In the bio-psycho-social perspective, assessing quality 
of life in oncology is crucial to monitor the adjustment 
process of cancer patients to family, social and work-
ing life and, when needed, to deliver specific interven-
tion programmes 4. Chemotherapy has been associated 
with reduced quality in physical and mental domains, 
together with body image dissatisfaction and reduced 
sexual functioning 5 6. Furthermore, patients experienc-
ing recurrence of disease suffered greater reduction 
in quality of life, particularly in symptom severity and 
physical functioning, than patients with metastatic dis-
ease or primary, non-metastatic disease 7. 
Given its specific characteristics of aggressiveness and 
uncertainty, a diagnosis of cancer rouses anxieties of de-
struction, triggering extreme and archaic defence mech-
anisms. According to the literature, denial is the most 
frequent defence mechanism used by cancer patients to 
manage a diagnosis of breast cancer and its consequenc-
es 8. While, on the one hand, denial clearly represents a 
primitive and global strategy, which often leads to gross 
distortion of reality, on the other hand, denial might be 
an adaptive strategy to protect the patient against over-
whelming events and emotions 9. 
Another well-known feature of cancer patients is the dif-
ficulty in identifying feelings and in expressing emotions 
that is currently defined by the term “alexithymia” 10. Evi-
dence suggests that alexithymia could represent a possi-
ble risk factor for medical and psychiatric disorders. Al-
though high levels of alexithymia have been related to 
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• The European Organization for Research and Treat-
ment for Cancer Quality of Life (EORTC QLQ-C30) 19: 
a self-report questionnaire used to study the quality of 
life in cancer patients. It investigates the stage of ill-
ness through nine scales: five functional scales (physi-
cal, role, cognitive, emotional, social), three symptom 
scales (fatigue, pain, nausea/vomiting) and a global 
health status scale. Moreover, it includes six single-
item scales assessing symptoms typically associated 
with cancer and with cancer treatment, such as dysp-
noea, insomnia, loss of appetite, constipation, diar-
rhoea and financial difficulties; there are also some 
items inquiring sexuality. To better understand the spe-
cific conditions of breast cancer patients, the module 
EORTC BR23 was also administered that covers the 
effects of therapy, body perception, sphere of sexual-
ity and vision of the future in this specific population. 
• The Toronto Alexithymia Scale (TAS-20)  20: a self-re-
port questionnaire consisting in 20  items assessing 
alexithymia, and specifically difficulty in identifying 
feelings and distinguishing them from somatic sen-
sations (F1), difficulty in describing feelings (F2) and 
externally oriented thinking, i.e. the tendency of in-
dividuals to focus their attention on external events 
rather than internal thoughts and emotions (F3).
• The Defense Mechanisms Inventory (DMI)  21: a pa-
per-and-pencil test that evaluates the defence mech-
anisms, classified according to five defensive styles: 
Turning Against Object (TAO) that means dealing with 
internal or external conflicts by attacking an external 
frustrating object; Projection (PRO) meaning project-
ing out unacceptable characteristics of the subjects 
to an external object; Principalisation (PRN) that is 
isolating, intellectualising and rationalising unac-
ceptable emotions, thoughts, or behaviours; Turning 
Against Self (TAS), i.e. dealing with frustrating experi-
ence by turning aggression against oneself; Reversal 
(REV), a mechanism by which negative emotions are 
managed by enacting positive or neutral behaviour in 
response to frustrating objects, which normally evoke 
a negative reaction: defences such as negation, de-
nial, reaction formation and repression are subsumed 
under this category.
In addition to the above, a socio-demographic question-
naire was also administered to collect socio-demograph-
ic data.
Statistical analysis 
Analyses were carried out using SPSS version 18.0. Com-
parisons between groups were performed using one-way 
ANOVA and post-hoc Bonferroni and Dunnet’s C tests. 
When appropriate, analyses were controlled for possible 
confounders (i.e. any variable that was associated both with 
immune system dysfunctions, lower quality of life, and 
anxiety and depression symptoms, the role of alexithymia 
in the onset and course of breast cancer patients is not ful-
ly clear 11 12. Indeed, some authors consider alexithymia 
a dynamic reaction to the illness in recently diagnosed 
patients, declining during subsequent phases 13 14: In this 
view, cancer patients’ inhibited behaviour can be regard-
ed as a time-limited reaction rather than a stable person-
ality trait 15. Alexithymia can be defined as a reaction to 
unpleasant emotional states in which individuals restrict 
their emotional range to mitigate painful experiences. By 
contrast, others suggested a distinction between primary 
alexithymia, as a stable personality trait, and secondary 
alexithymia, as a transitory reaction and a coping mecha-
nism through which individuals avoid unpleasant emo-
tional states by severely restricting emotional range 16 17. 
For instance, an Italian survey of women with breast can-
cer suggested that these patients may have something in 
common with so-called psychosomatic patients in terms 
of constrained imagination and fantasy, and difficulty in 
verbalising emotions 18. 
Our study aims to compare psychological adjustment and 
cancer- and treatment- related symptoms between patients 
with breast cancer at different stages of the disease (i.e. 
receiving chemotherapy for metastatic disease, receiving 
adjuvant chemotherapy and in disease-free follow-up). 
Additionally, the study seeks to investigate, whether, be-
sides the effect of the illness stage, quality of life is also 
affected by alexithymia and defence mechanisms.
Materials and methods
Participants
A convenience sample was recruited among women af-
fected by breast cancer, who were previously treated with 
surgical therapy, admitted to the outpatient clinic of the 
Cancer Surgery Department of a private hospital of Paler-
mo. The study was approved by the clinical team. Patients 
were recruited on voluntary basis, were fully informed 
about the aims and the risks and benefits of the study 
and signed an informed consent sheet. Patients were di-
vided into three groups according to disease stage: the 
first group consisted in patients who were receiving ad-
juvant chemotherapy after surgery (chemotherapy), the 
second group in patients in follow-up after treatment of 
neoplastic disease (disease-free survival/follow-up) and 
the third group of patients was undergoing chemotherapy 
treatment for metastatic disease (metastatic). 
Instruments
The following instruments were administered to partici-
pants by clinical psychologists.
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perienced worse sexual functioning than the metastatic 
(Table IIb). For these QOL domains (i.e. social function-
ing) or symptoms (i.e. pain, and side effects) that were 
also associated with education level, analyses were re-
peated using ANCOVA: the effect of group remained 
significant and, additionally, higher education was also 
associated with poorer social functioning (B = -14.582, 
95% CI -23.082 to -6.082, t = -3.402, p = 0.001).
Alexithymia total score and, specifically, difficulty in 
identifying feelings (TAS-20 F1) and externally oriented 
thinking (TAS-20 F3) were higher in patients with progres-
sive disease compared to the other groups, which showed 
similar mean scores. Furthermore, difficulty in expressing 
feelings (TAS-20 F2) was higher in the metastatic group 
only compared to the adjuvant chemotherapy group (see 
Table  III). Since in this sample alexithymia was associ-
ated with lower education, analyses were covariated for 
education levels: the effect of group remained significant, 
but, in addition, higher education achievement was as-
sociated with lower alexithymia total score (B = -5.988, 
95% CI -10.515 to -1.460, t  =  -2.622, p  =  0.010), re-
duced F2 difficulty in expressing feelings (B  =  -8.894, 
95% CI  -16.887 to -0.902, t  =  -2.206, p = 0.030) and 
lower F3 externally oriented thinking (B = 7.433, 95% 
CI -12.323 to -2.543, t = -3.014, p = 0.003). 
We found that the TAS-20 difficulty in identifying feeling 
negatively correlated with all the functional scales of EO-
RTC (physical functioning Pearson’s r = -0.419 p < 0.001; 
role functioning r = -0.312, p = 0.001; emotional function-
ing r = -0.422 p < 0.001; cognitive functioning r = -0.318, 
p = 0.001; social functioning r = -0.412, p < 0.001). How-
ever, TAS-20 F2 difficulty in expressing feelings was only 
related to physical functioning (r = -0.276, p = 0.004) and 
the disease stage and with any of the psychological vari-
ables) using ANCOVA. The correlation between variables 
was tested using bivariate Pearson’s correlation. Finally, the 
combined effect of groups, alexithymia and defence mecha-
nism on quality of life domains was assessed using linear 
regression models.
Results
Our sample consisted of 110 subjects. 41 patients were 
receiving adjuvant chemotherapy (Chemotherapy), 40 pa-
tients chemotherapy for metastatic disease (Metastatic) 
and 29 were disease-free patients in follow-up (Follow-
up). The description of sample is reported in Table I. The 
three groups were different only in terms of education 
with the follow-up group that achieved higher education 
level (meaning more than 9 years spent at school) than 
the other two groups. 
Mean score of the quality of life (EORTC QLQ-C30, 
Global Health Status QOL) scale and mean scores at the 
physical, role, emotional and social functional scales 
were significantly lower in metastatic patients than in dis-
ease-free patients. Furthermore, the former showed more 
severe symptoms of fatigue, nausea, pain and appetite 
loss than patients in follow-up. In addition, financial dif-
ficulties were less pronounced in the follow-up patients 
compared to the other groups (Table IIa). 
Regarding the specific features of QoL in breast cancer 
patients, persons with metastatic cancer showed lower 
body image satisfaction compared to persons in the fol-
low-up stage. This group was, obviously, less upset by 
side effects and hair loss than the other two groups. In 
addition, patients undergoing adjuvant chemotherapy ex-
Table I.
Demographic features of the sample.
  Follow-up
n = 29
Chemotherapy
n = 41
Metastatic
n = 40
anova’s F test/ 
chi square
p
age mean (sd) 54.1 (10.2) 54.2 (9.2)  57.9 (9.9) 1.589 0.209
education 
Lower education (< 8 ys) n (%) 11 (27.5%) 24 (58.5%) 17 (58.6%) 9.859 0.007
Higher education (> 9 ys) n (%) 29 (72.5%) 17 (41.5%) 12 (41.4%)
Occupation
Unoccupied n (%) 23 (57.5%) 25 (61.0%) 18 (62.1%) 0.172 0.918
Occupied n (%) 17 (42.5%) 16 (39.0%) 11 (37.9%)
Marital status
Married n (%) 35 (87.5%) 33 (80.5%) 22 (75.9%) 1.608 0.447
Unmarried n (%) 5 (12.5%) 8 (19.5%) 7 (24.1%)
sd: Standard deviation; ys: Years of instruction.
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role functioning (r = -0.224, p = 0.019), and TAS-20 ex-
ternally oriented thinking only correlated with physical 
functioning (r = -0.215, p = 0.025).
All the groups scored higher in the principalisation (PRN) 
defensive style than in the other defensive styles, with no 
differences between groups (see Table  IV). Furthermore, 
turning against the object (TAO) was positively related to 
EORTC physical functioning (Pearson’s r = 0.273 p = 0.004) 
and role functioning (Pearson’s r = 0.234 p = 0.014), while 
principalisation (PRN) negatively correlated with EORTC 
emotional functioning (Pearson’s r = -0.217 p = 0.023).
Finally, considering the results of the univariate analyses, 
we assessed the combined effect of the groups, TAS-20 
alexithymia scales, and DMI defence styles on the EORTC 
functional scales. Independent variables were entered in 
three blocks: in the first block we included stage of the ill-
ness and education level; in the second block the TAS-20 
subscales that correlated with EORTC scales; in the third 
block the DMI defence styles that correlated with EORTC 
scales. As described in Table V, controlling for effect of 
the other psychological variables, the stage of the illness 
significantly predicted only the social functioning score. 
In contrast, TAS-20 F1, difficulty in identifying feelings 
predicted lower quality of life in all EORTC domain and 
DMI TAO better physical functioning and role function-
ing. Overall, the final models explained between 8% and 
26% of the variance in quality of life.
Discussion and conclusion
Although EORTC global health status (range 63.4 - 76.7) 
and functional domains score (range 60.6 - 91.7) show 
that – on average – our sample describe their quality of 
life as medium-high 19, the different stages of breast can-
cer were related to specific issues in psychological ad-
justment and physical symptoms.
Compared to the other groups, patients receiving chem-
otherapy for metastatic disease showed higher global 
impairment, poorer quality of life in several domains 
and experienced more severe cancer-related and treat-
ment-related symptoms. Specifically, after controlling 
for the effect of multiple testing, metastatic patients 
showed greater physical impairment and greater diffi-
Table IIa.
EORTC QLQ-C30 scores across groups.
  Follow-up Chemotherapy Metastatic Crude 
anova’s F test
(p value)
adjusted 
anova’s F test
(p value)
Comparison 
between groups
Global Health Status Qol
M (sd)
76.7 (17.4) 71.4 (19.8) 63.4 (18.8) 4.253 (0.017) M < C*
Functional scales
Physical functioning (PF2) M (sd) 86.4 (15.2) 80.5 (15.3) 62.5 (26.9) 9.224 (< 0.001) M < C; M < FU**
Role functioning (RF2) M (sd) 89.4 (17.9) 82.8 (20.6) 60.9 (38.8) 7.772 (0.001) M < C; M < FU**
Emotional functioning (EF) M (sd) 79.8 (19.5) 75.1 (20.5) 60.6 (27.5) 6.530 (0.002) M < C; M < FU*
Cognitive functioning (CF) M (sd) 83.7 (18.2) 82.7 (19.1) 82.2 (27.4) 0.044 (0.957)
Social functioning (SF) M (sd) 91.7 (13.4) 83.1 (22.0) 74.6 (31.0) 5.037 (0.010) 8.110 (0.001) M < FU**
Symptom scales
Fatigue (FA) M (sd) 19.7 (24.4) 27.0 (22.8) 43.0 (28.7) 7.308 (0.001) M > C; M > FU*
Nausea and vomiting (NV) M (sd) 3.4 (12.6) 8.3 (14.8) 19.3 (29.1) 4.251 (0.019) M > FU**
Pain (PA) M (sd) 13.4 (16.4) 18.8 (19.4) 30.5 (30.2) 3.952 (0.024) 3.970 (0.022) M > FU**
Dyspnoea (DY) M (sd) 10.1 (17.1) 9.6 (18.4) 26.3 (34.9) 2.900 (0.063)
Insomnia (SL) M (sd) 15.2 (21.2) 26.6 (29.8) 31.9 (33.8) 3.204 (0.045)
Appetite loss (AP) M (sd) 4.2 (11.1) 3.2 (9.9) 22.8 (30.9) 5.401 (0.007) M > C; M > FU**
Constipation (CO) M (sd) 9.3 (22.7) 16.1 (24.6) 23.9 (33.0) 2.255 (0.113)
Diarrhoea (DI) M (sd) 4.2 (13.5) 4.8 (13.9) 10.3 (21.9) 0.881 (0.419)
Financial difficulties (FI) M (sd) 5.8 (14.8) 19.3 (24.4) 26.3 (35.9) 7.289 (0.002) FU < C; FU < M**
* Bonferroni’s test significant at 0.05 level; ** Dunnett C’s test significant at 0.05 level; M: Metastatic group; C: Chemotherapy group; FU: Follow-
up group; m: Mean; sd: Standard deviation.
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above are obviously related to the greater impact of can-
cer on family and social life. When the other personality 
features were taken in account, illness stage significantly 
predicted EORTC social functioning. This confirms the 
culty in daily life activities and employment. Moreover, 
they reported more often than the other groups to feel 
anxious, worried, or depressed and to be less satisfied 
of their body image than patients in follow-up. All the 
Table IIb.
EORTC BR23 scores across the three groups.
  Follow-up Chemotherapy Metastatic Crude anova’s 
F (p value)
adjusted 
anova’s F test
(p value)
Comparison 
between 
groups
Functional scales
Body image (BRBI) M (sd) 86.5 (22.9) 74.2 (24.1) 72.1 (24.1) 4.013 (0.023) M < FU**
Sexual functioning (BRSEF) 
M (sd)
25.9 (26.3) 15.6 (19.1) 36.7 (40.4) 4.649 (0.012) C < M*
Sexual enjoyment (BRSEE) 
M (sd)
23.8 (27.4) 12.9 (21.9) 20.6 (34.9) 1.633 (0.200)
Future perspective (BRFU) 
M (sd)
66.6 (30.8) 59.6 (31.0) 48.3 (28.9) 3.139 (0.053)
Symptom scales
Systemic therapy side effects 
(BRST) M (sd)
8.1 (9.3) 21.9 (14.5) 29.7 (20.3) 19.017 (< 0.001) 15.802 (< 0.001) C > F; M > F*
Breast symptoms (BRBS) M (sd) 8.2 (14.0) 13.3 (12.8) 9.6 (12.7) 1.549 (0.220)
Arms symptoms (BRAS) M (sd) 16.0 (20.5) 21.6 (20.9) 20.4 (20.5) 0.798 (0.454)
Upset by hair loss (BRHL) 
M (sd)
0.6 (3.5) 31.5 (38.5) 25.1 (36.2) 11.399 (< 0.001) C > F; M > F*
* Bonferroni’s test significant at 0.05 level; ** Dunnett C’s test significant at 0.05 level; M: Metastatic group; C: Chemotherapy group; FU: Fol-
low-up group; m: Mean; sd: Standard deviation.
Table III.
Toronto Alexithymia Scale-20 scores across the three groups.
Follow-up Chemotherapy Metastatic Crude 
anova’s F test
(p value)
adjusted 
anova’s F test
(p value)
Comparison 
between groups*
TaS-20
M (sd) 42.5 (10.9) 44.2 (11.0) 57.6 (13.3) 15.917 
(< 0.001)
14.208 
(< 0.001)
M > C
M > FU
F1 
M (sd) 39.8 (17.2) 41.5 (15.9) 55.3 (22.8) 6.772
(0.002)
6.209 
(0.003)
M > C
M > FU
F2
M (sd) 47.9 (19.9) 46.2 (19.8) 58.9 (22.1) 3.624
(0.030)
3.367 
(0.038)
M > C
F3
M (sd) 43.2 (13.4) 46.9 (13.4) 58.5 (10.5) 12.692
(< 0.001)
10.479
(< 0.001)
M > C
M > FU
* Bonferroni’s test significant at 0.05 level; TAS-20: Alexithymia total score; F1: Difficulty in identifying feelings; F2: Difficulty in expressing emo-
tions; F3: Externally oriented thinking; m: Mean; sd: Standard deviation; M: Metastatic group; C: Chemotherapy group; FU: Follow-up group.
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clinical populations, including oncologic cohorts, sup-
port the view that alexithymia is mainly a relatively stable 
personality trait, but to a small extent, it is susceptible 
to be increased under psychological distress 28-30. In this 
perspective, and with the limitation of a cross-sectional 
study (i.e. lack of information about alexithymia before 
the onset of cancer disease), the higher score in the met-
astatic group might be interpreted as a reaction to the 
stress conveyed by the progression of the disease. 
In addition to the course of the disease, TAS-20 factor 1, 
difficulty in identifying feelings, was significantly relat-
ed to all the EORTC functional subscales, even when 
the effect of other potential predictors was taken into ac-
count, contributing to considerably lowering the quality 
of life of patients affected by breast cancer, independent-
ly of their illness stage. The finding is consistent with a 
previous study on cancer patients showing that, together 
with abnormal illness behaviour, difficulty in identifying 
crucial impact of cancer on the interpersonal and so-
cial relationship 22 as well as on sexual functioning 23 24. 
In fact, sexual functioning scores were very low across 
groups and, particularly, in the group receiving adjuvant 
chemotherapy. In addition, as expected, both patients 
undertaking chemotherapy for primary or metastatic 
disease were more upset by cancer-related (i.e. fatigue, 
nausea, pain, and appetite loss) and treatment-related 
symptoms (i.e. systemic therapy side effects and hair 
loss) than disease-free patients.
Self-reported alexithymia was significantly higher in the 
metastatic patients group than in the other two, being in 
the range 52-60 that is classified as “possible alexithy-
mia” 20. Although several longitudinal studies have indi-
cated alexithymia as a stable personality trait 25 26, some 
research pointed out secondary, or reactive, alexithymia 
in breast cancer patients  27 as a defensive reaction to 
stressful events. Furthermore, several studies on different 
Table IV.
DMI scores across the three groups.
Follow-up Chemotherapy Metastatic Crude anova’s F 
(p value)
TaO 
M (sd) 32.7 (8.1) 33.5 (9.0) 33.9 (10.5) 0.959 (0.386)
PRO 
M (sd) 38.4 (6.3) 38.7 (6.3) 33.1 (4.6) 0.707 (0.495)
PRN 
M (sd) 51.0 (6.3) 49.9 (7.5) 50.5 (6.8) 0.279 (0.757)
TaS 
M (sd) 37.0 (7.7) 35.0 (6.7) 36.6 (7.0) 0.883 (0.416)
ReV 
M (sd) 41.1 (7.5) 40.2 (9.0) 41.7 (7.7) 0.294 (0.746)
TAO: Turning Against Object; PRO: Projection; PRN: Principalisation; TAS: Turning Against Self; REV: Reversal; m: Mean; sd: Standard deviation..
Table V.
Effect of stage of the illness, education level, alexithymia, defence style and the functional scale of EORTC.
Predictors b (95% CI) anova’s F (p value) R2 adj. R2
Physical functioning TAS-20 F1
DMI TAO
-0.358 (-0.586 – -0.194)
0.298 (0.293 – 1.086)
6.920 (< 0.001) 0.289 0.247
Role functioning TAS-20 F1
DMI TAO
-2.720 (-0.631 – - 0.099)
2.904 (0.250 – 1.329)
4.795 (0.001) 0.189 0.149
Emotional functioning TAS-20 F1 -0.460 (-0.780 – -0.328) 6.502 (< 0.001) 0.200 0.169
Cognitive functioning TAS-20 F1 -0.318 (-0.547 – -0.l45) 3.941 (0.010) 0.101 0.076
Social functioning Group
education level
TAS-20 F1
0.215 (1.193 – 10.411)
0.315 (6.484 – 22.684)
-0.456 (-0.758 – -0.332)
10.460 (< 0.001) 0.287 0.259
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turning against self). Moreover, turning against the ob-
ject might be related with higher level of energy and, 
indirectly, with reduced physical impairment and lower 
disability in performing working and daily life tasks. 
Unfortunately, the cross-sectional design prevents any 
conclusion regarding direction of causality.
In summary, this study underlined the relevance of dif-
ficulty in emotional processing and defence mechanisms 
in modulating psychological adjustment in women af-
fected by breast cancer, suggesting that these might 
represent targets of psychological intervention for this 
population. However, the study has several limitations: 
the use of a cross-sectional design does not allow to es-
tablish whether difficulty in identifying feelings and TAO 
defence profile might be regarded as liability factors for 
poor quality of life, rather than its effects. Furthermore, 
the use of a convenience sample may limit, to some ex-
tent, the generalisability of the findings. Since this study 
relied on self-reported information, the effect of recall 
bias cannot be fully excluded, though the effect of TAS-
20 F1 and DMI TAO were still significant after adjusting 
for stage of illness. Finally, it cannot be excluded that the 
relation between quality of life and personality factors 
was influenced by other non-assessed variables (includ-
ing characteristics of the tumour, stressful events, social 
support and psychiatric comorbidities). Therefore, further 
investigations are warranted. 
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